Overview

Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study is intended to assess the PK and safety of a single dose of IV and oral formulations of lefamulin in adults with CF.
Phase:
Phase 1
Details
Lead Sponsor:
Nabriva Therapeutics AG
Treatments:
Lefamulin